Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma

Larocca, A; Bonello, F; Gaidano, G; D'Agostino, M; Offidani, M; Cascavilla, N; Capra, A; Benevolo, G; Tosi, P; Galli, M; Marasca, R; Giuliani, N; Bernardini, A; Antonioli, E; Rota-Scalabrini, D; Cellini, C; Pompa, A; Monaco, F; Patriarca, F; Di Toritto, TC; Corradini, P; Tacchetti, P; Boccadoro, M; Bringhen, S

Larocca, A (corresponding author), Univ Torino, Azienda Osped Univ Citta Salute & Sci Torino, Div Hematol, Myeloma Unit, Via Genova 3, I-10126 Turin, Italy.

BLOOD, 2021; 137 (22): 3027

Abstract

Lenalidomide-dexamethasone (Rd) is standard treatment for elderly patients with multiple myeloma (MM). In this randomized phase 3 study, we investigat......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索